Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Wang, Wei ^a   Zhang, Xu ^a   Qin, Jiang Jiang ^a   Voruganti, Sukesh ^a   Nag, Subhasree Ashok ^a   Wang, Ming Hai ^a   Wang, Hui ^b   Zhang, Ruiwen ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

25 METHOXYL DAMMARANE 3BETA, 12BETA, 20 TRIOL; ANTINEOPLASTIC AGENT; GINSENOSIDE; PROTEIN MDM2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SCREENING; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MIGRATION INHIBITION; MOUSE; NONHUMAN; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GINSENOSIDES; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MDM2; TETRACYCLINE; TIME FACTORS; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

PANAX GINSENG; PANAX NOTOGINSENG;

EID: 84864188733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041586     Document Type: Article

References (45)

1. DeSantis C, Siegel R, Bandi P, Jemal A, (2011) Breast cancer statistics. CA Cancer J Clin 61: 409-418.
2. Croce CM, (2008) Oncogenes and cancer. N Engl J Med 358: 502-511.
3. Helms S, (2004) Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 9: 259-274.
4. Zhao Y, Wang W, Han L, Rayburn E, Hill D, et al. (2007) Isolation, structural determination, and evaluation of the biological activity of 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol [20(S)-25-OCH3-PPD], a novel natural product from Panax notoginseng. Med Chem 3: 51-60.
5. Wang W, Zhao Y, Rayburn ER, Hill DL, Wang H, et al. (2007) In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol 59: 589-601.
6. Wang W, Rayburn ER, Hao M, Zhao Y, Hill DL, et al. (2008) Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 68: 809-819.
7. Wang W, Rayburn ER, Hang J, Zhao Y, Wang H, et al. (2009) Anti-lung cancer effects of novel ginsenoside 25-OCH3-PPD. Lung Cancer 65: 306-311.
8. Wang W, Rayburn ER, Zhao Y, Wang H, Zhang R, (2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 278: 241-248.
9. Wang W, Wang H, Rayburn ER, Zhao Y, Hill DL, et al. (2008) 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action. Br J Cancer 98: 792-802.
10. Rayburn E, Zhang R, He J, Wang H, (2005) MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 5: 27-41.
11. Onel K, Cordon-Cardo C, (2004) MDM2 and prognosis. Mol Cancer Res 2: 1-8.
12. Iwakuma T, Lozano G, (2003) MDM2, an introduction. Mol Cancer Res 1: 993-1000.
13. Levine AJ, Oren M, (2009) The first 30 years of p53: growing ever more complex. Nature Rev Cancer 9: 749-758.
14. Vogelstein B, Lane D, Levine AJ, (2000) Surfing the p53 network. Nature 408: 307-310.
15. Zhang R, Wang H, (2000) MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Design 6: 393-416.
16. Chène P, (2003) Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 3: 102-109.
17. Zhang Z, Li M, Wang H, Agrawal S, Zhang R, (2003) Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A 100: 11636-11641.
18. Li M, Zhang Z, Hill DL, Wang H, Zhang R, (2007) Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 67: 1988-1996.
19. Wang W, Rayburn ER, Velu SE, Nadkarni DH, Murugesan S, et al. (2009) In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 15: 3511-3518.
20. Wang W, Rayburn ER, Velu SE, Chen D, Nadkarni DH, et al. (2010) A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action. Breast Cancer Res Treat 123: 321-331.
21. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, et al. (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10: 1321-1328.
22. Araki S, Eitel JA, Batuello CN, Bijangi-Vishehsaraei K, Xie XJ, et al. (2010) TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest 120: 290-302.
23. Barak Y, Juven T, Haffner R, Oren M, (1993) Mdm2 expression is induced by wild type p53 activity. EMBO J 12: 461-468.
24. Momand J, Zambetti GP, Olson DC, George D, Levine AJ, (1992) The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
25. Chen CY, Oliner JD, Zhan Q, Fornace AJ Jr, Vogelstein B, et al. (1994) Interactions between p53 and mdm2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci U S A 91: 2684-2688.
26. Chen J, Wu X, Lin J, Levine AJ, (1996) Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16: 2445-2452.
27. Haupt Y, Maya R, Kazaz A, Oren M, (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
28. Kubbutat MHG, Jones SN, Vousden KH, (1997) Regulation of p53 stability by mdm2. Nature 387: 299-303.
29. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, et al. (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and mdm2. Proc Natl Acad Sci U S A 95: 8292-8297.
30. Bothner B, Lewis WS, DiGiammarino EL, Weber JD, Bothner SJ, et al. (2001) Defining the molecular basis of Arf and Hdm2 interactions. J Mol Biol 314: 263-77.
31. Xiao Z, Chen J, Levine AJ, Modjtahedi N, Xing J, et al. (1995) Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698.
32. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, et al. (1995) Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691-694.
33. Xu H, Zhang Z, Li M, Zhang R, (2010) MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change. J Biol Chem 285: 18407-18414.
34. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A, (1998) Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A 95: 1508-1512.
35. Peng Y, Chen L, Li C, Lu W, Agrawal S, et al. (2001) Stabilization of the MDM2 oncoprotein by mutant p53. J Biol Chem 276: 6874-6878.
36. Pan Y, Haines DS, (1999) The pathway regulating MDM2 protein degradation can be altered in human leukemic cells. Cancer Res 59: 2064-2067.
37. Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, et al. (2000) Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103: 321-330.
38. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
39. Christiansen JJ, Rajasekaran AK, (2006) Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66: 8319-8326.
40. Yang JY, Zong CS, Xia W, Wei Y, Ali-Seyed M, et al. (2006) MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol 26: 7269-7282.
41. Polański R, Warburton HE, Ray-Sinha A, Devling T, Pakula H, et al. (2010) MDM2 promotes cell motility and invasiveness through a RING-finger independent mechanism. FEBS Lett 584: 4695-4702.
42. Phelps M, Darley M, Primrose JN, Blaydes JP, (2003) p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor α-positive breast cancer cells. Cancer Res 63: 2616-2623.
43. Chen L, Gilkes DM, Pan Y, Lane WS, Chen J, (2005) ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J 24: 3411-3422.
44. Liu G, Chen X, (2006) DNA polymerase eta, the product of the xeroderma pigmentosum variant gene and a target of p53, modulates the DNA damage checkpoint and p53 activation. Mol Cell Biol 26: 1398-1413.
45. Chen D, Zhang Z, Li M, Wang W, Li Y, et al. (2007) Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene 26: 5029-5037.